Nowadays, ALK small-molecule inhibitors are among the most promising agents in several high-risk cancers, based on the fact that ALK, when activated by mutation, amplification or gene rearrangement, becomes highly oncogenic [33,34,35,36]. Here, ALK is linked to cancer.